<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02224534</url>
  </required_header>
  <id_info>
    <org_study_id>D5130C00138</org_study_id>
    <nct_id>NCT02224534</nct_id>
  </id_info>
  <brief_title>Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction</brief_title>
  <acronym>HEALING-AMI</acronym>
  <official_title>High PlatElet Inhibition With TicAgrelor to Improve Left Ventricular RemodeLING in Patients With ST-segment ElevAtion Myocardial Infarction: the HEALING-AMI Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University Heart Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Changwon Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gyeongsang National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the novel role of ticagrelor to improve long-term LV&#xD;
      remodeling following ST-segment elevation myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators designed the HEALING-AMI study to compare the influence of ticagrelor (180&#xD;
      mg loading and 90 mg twice daily maintenance) vs. clopidogrel (600 mg loading and 75 mg daily&#xD;
      maintenance) on long-term left ventricular (LV) remodeling measured by 3D echocardiography in&#xD;
      STEMI patients undergoing primary PCI.&#xD;
&#xD;
      The primary objective of the HEALING-AMI study is to demonstrate the novel role of long-term&#xD;
      ticagrelor therapy in reducing the risk of LV remodeling,. The secondary objectives are to&#xD;
      reveal the cross-talk between platelet and inflammatory process in ST-segment elevation&#xD;
      myocardial infarction (STEMI) patients. Moreover, this study will determine whether the high&#xD;
      platelet inhibition by ticagrelor culminate the protection of infarcted myocardium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LV remodeling index (%)</measure>
    <time_frame>Interval change between baseline and 6 months after the index events</time_frame>
    <description>Real time 3D-echocardiography data sets will be analyzed with available 4D-LV Analysis software (e.g. TomTec Imaging Systems, Unterschleisheim, Germany) in the core lab.&#xD;
Left ventricular (LV) remodeling index: a relative change in LV end-diastolic volume (LVEDV) seen at 6-month follow-up compared with the baseline during admission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NT-proBNP level at 6 months</measure>
    <time_frame>6 months after the index events</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change of LVESVI, LVEDVI and LVEF</measure>
    <time_frame>Interval change between baseline and 6 months after the index events</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of adverse LV remodeling</measure>
    <time_frame>Interval change between baseline and 6 months after the index events</time_frame>
    <description>Adverse LV remodeling: a relative &gt; 20% increase in LVEDV seen at 6-month follow-up compared with the baseline during admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of platelet reactivity</measure>
    <time_frame>At the time of PCI, 3 days and 1 month after the events</time_frame>
    <description>Measured by VerifyNow P2Y12 assay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Post-PCI angiographic perfusion indicators: TIMI flow grade, myocardial blush grade, corrected TIMI frame count</measure>
    <time_frame>Just after primary PCI</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>EKG change: ST-segment elevation resolution (%), complete ST-segment resolution</measure>
    <time_frame>Baseline, 60 minutes after the PCI.</time_frame>
    <description>complete ST-segment resolution: ST-segment resolution ≥70%</description>
  </other_outcome>
  <other_outcome>
    <measure>Level of hs-CRP</measure>
    <time_frame>At the time of PCI, 1 month and 6 months after the events</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding events based on BARC or PLATO definition</measure>
    <time_frame>6 months after the events</time_frame>
    <description>BARC definition for bleeding is defined as type 1, 2, 3 (3a, 3b and 3c), 4, and 5 (5a and 5b), according to the Bleeding Academic Research Consortium classification.&#xD;
Type 1 (nuisance or superficial bleeding).&#xD;
Type 2 (internal bleeding).&#xD;
Type 3a (TIMI minor bleeding).&#xD;
Type 3b (TIMI major bleeding).&#xD;
Type 3c (life threatening bleeding).&#xD;
Type 4 (CABG-related bleeding).&#xD;
Type 5a (probable fatal bleeding).&#xD;
Type 5b (definite fatal bleeding). Bleeding events pertaining to type 1 to 3a are considered as minor bleeding and those pertaining to type 3b to 5b as major bleeding.&#xD;
PLATO definition for bleeding&#xD;
Major life-threatening bleeding.&#xD;
Other major bleeding.&#xD;
Minor bleeding.&#xD;
The case report form (CRF) collects the event history of bleeding during admission and at 1 month and 6 months. Occurrences of major, minor, and combined major and minor bleeding events will be compared between groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac MRI (Substudy): LV remodeling index</measure>
    <time_frame>Three days and 6 months after the events</time_frame>
    <description>Measured at A*STAR-NUS Clinical Imaging Research Centre, Singapore</description>
  </other_outcome>
  <other_outcome>
    <measure>Level of inflammatory markers (Substudy)</measure>
    <time_frame>During hospitalization and at 1 month after the events</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">326</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor and Clopidogrel.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients assigned to the TICA group have loading dose of ticagrelor 180 mg just after the randomization, and then ticagrelor 90 mg twice daily during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients assigned to the CLPD group have loading dose of clopidogrel 600 mg just after the randomization, and then clopidogrel 75 mg daily should be maintained during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose</description>
    <arm_group_label>Ticagrelor and Clopidogrel.</arm_group_label>
    <other_name>Brillinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years and older.&#xD;
&#xD;
          -  First-time onset STEMI patients uneventfully treated with primary PCI within 12 hours&#xD;
             of onset of symptom.&#xD;
&#xD;
          -  Infarct-related artery with TIMI 0, 1, or 2 grade flow at the time of initial&#xD;
             diagnostic angiography (before wire passage).&#xD;
&#xD;
          -  proximal or mid-portion lesion of epicardial coronary artery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of myocardial infarction.&#xD;
&#xD;
          -  Left bundle branch block on ECG at the time of screening.&#xD;
&#xD;
          -  Cardiogenic shock at the time of randomization.&#xD;
&#xD;
          -  Refractory ventricular arrhythmias or atrial fibrillation.&#xD;
&#xD;
          -  New York Heart Association class IV congestive heart failure.&#xD;
&#xD;
          -  Severe or malignant hypertension (SBP&gt; 180 and/or DBP&gt; 120 mmHg).&#xD;
&#xD;
          -  Fibrinolytic therapy.&#xD;
&#xD;
          -  History of hemorrhagic stroke.&#xD;
&#xD;
          -  Intracranial neoplasm, arteriovenous malformation, or aneurysm.&#xD;
&#xD;
          -  Ischemic stroke within 3 months prior to screening.&#xD;
&#xD;
          -  Platelet count &lt; 100,000/mm3 or hemoglobin &lt; 10 g/dL.&#xD;
&#xD;
          -  A need for oral anticoagulation therapy that cannot be safely discontinued for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Women who are known to be pregnant, have given birth within the past 90 days, or are&#xD;
             breast-feeding.&#xD;
&#xD;
          -  Unable to cooperate with protocol requirements and follow-up procedures.&#xD;
&#xD;
          -  A history of P2Y12 receptor inhibitor pretreatment (at least prior 1 month).&#xD;
&#xD;
          -  An increased risk of bradycardia.&#xD;
&#xD;
          -  Concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongwhi Park, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gyeongsang National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young-Hoon Jeong, MD.,PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gyeongsan National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongwhi Park, MD.,PhD.</last_name>
    <phone>+82-55-750-8059</phone>
    <email>angio2000@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young-Hoon Jeong, MD.,PhD.</last_name>
    <phone>+82-55-214-3721</phone>
    <email>goodoctor@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Bejing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yundai Chen, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>CHONRANAM-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Joon Hong, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Bundang</city>
        <state>Gyeongki-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong-Won Suh, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changwon Samsung Medical Center</name>
      <address>
        <city>Changwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ju Hyeon Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Chungju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sang Yeub Lee, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jang Hoon Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jae-Hyeong Park, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Korea</city>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yongwhi Park, MD.,PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young-Hoon Jeong, MD.,PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Won Kim, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eun-Seok Shin, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeong Su Kim, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Heart Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>August 20, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2014</study_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gyeongsang National University Hospital</investigator_affiliation>
    <investigator_full_name>Yongwhi Park</investigator_full_name>
    <investigator_title>MD.,PhD.</investigator_title>
  </responsible_party>
  <keyword>ST elevation myocardial infarction.</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Left ventricular remodeling</keyword>
  <keyword>Platelet reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02224534
org study id: D5130C00138
nct id: NCT02224534
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: Yes
The purpose of the study is to evaluate the novel role of ticagrelor to improve long-term LV
      remodeling following ST-segment elevation myocardial infarction.
The investigators designed the HEALING-AMI study to compare the influence of ticagrelor (180
      mg loading and 90 mg twice daily maintenance) vs. clopidogrel (600 mg loading and 75 mg daily
      maintenance) on long-term left ventricular (LV) remodeling measured by 3D echocardiography in
      STEMI patients undergoing primary PCI.

      The primary objective of the HEALING-AMI study is to demonstrate the novel role of long-term
      ticagrelor therapy in reducing the risk of LV remodeling,. The secondary objectives are to
      reveal the cross-talk between platelet and inflammatory process in ST-segment elevation
      myocardial infarction (STEMI) patients. Moreover, this study will determine whether the high
      platelet inhibition by ticagrelor culminate the protection of infarcted myocardium.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: LV remodeling index (%)
time frame: Interval change between baseline and 6 months after the index events
description: Real time 3D-echocardiography data sets will be analyzed with available 4D-LV Analysis software (e.g. TomTec Imaging Systems, Unterschleisheim, Germany) in the core lab.
Left ventricular (LV) remodeling index: a relative change in LV end-diastolic volume (LVEDV) seen at 6-month follow-up compared with the baseline during admission.
measure: NT-proBNP level at 6 months
time frame: 6 months after the index events
measure: Absolute change of LVESVI, LVEDVI and LVEF
time frame: Interval change between baseline and 6 months after the index events
measure: Prevalence of adverse LV remodeling
time frame: Interval change between baseline and 6 months after the index events
description: Adverse LV remodeling: a relative > 20% increase in LVEDV seen at 6-month follow-up compared with the baseline during admission.
measure: Level of platelet reactivity
time frame: At the time of PCI, 3 days and 1 month after the events
description: Measured by VerifyNow P2Y12 assay
measure: Post-PCI angiographic perfusion indicators: TIMI flow grade, myocardial blush grade, corrected TIMI frame count
time frame: Just after primary PCI
measure: EKG change: ST-segment elevation resolution (%), complete ST-segment resolution
time frame: Baseline, 60 minutes after the PCI.
description: complete ST-segment resolution: ST-segment resolution ≥70%
measure: Level of hs-CRP
time frame: At the time of PCI, 1 month and 6 months after the events
measure: Bleeding events based on BARC or PLATO definition
time frame: 6 months after the events
description: BARC definition for bleeding is defined as type 1, 2, 3 (3a, 3b and 3c), 4, and 5 (5a and 5b), according to the Bleeding Academic Research Consortium classification.
Type 1 (nuisance or superficial bleeding).
Type 2 (internal bleeding).
Type 3a (TIMI minor bleeding).
Type 3b (TIMI major bleeding).
Type 3c (life threatening bleeding).
Type 4 (CABG-related bleeding).
Type 5a (probable fatal bleeding).
Type 5b (definite fatal bleeding). Bleeding events pertaining to type 1 to 3a are considered as minor bleeding and those pertaining to type 3b to 5b as major bleeding.
PLATO definition for bleeding
Major life-threatening bleeding.
Other major bleeding.
Minor bleeding.
The case report form (CRF) collects the event history of bleeding during admission and at 1 month and 6 months. Occurrences of major, minor, and combined major and minor bleeding events will be compared between groups.
measure: Cardiac MRI (Substudy): LV remodeling index
time frame: Three days and 6 months after the events
description: Measured at A*STAR-NUS Clinical Imaging Research Centre, Singapore
measure: Level of inflammatory markers (Substudy)
time frame: During hospitalization and at 1 month after the events
arm group label: Ticagrelor and Clopidogrel.
arm group type: Experimental
description: The patients assigned to the TICA group have loading dose of ticagrelor 180 mg just after the randomization, and then ticagrelor 90 mg twice daily during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
arm group label: Clopidogrel
arm group type: Active Comparator
description: The patients assigned to the CLPD group have loading dose of clopidogrel 600 mg just after the randomization, and then clopidogrel 75 mg daily should be maintained during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
intervention type: Drug
intervention name: Ticagrelor
description: Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
arm group label: Ticagrelor and Clopidogrel.
other name: Brillinta
intervention type: Drug
intervention name: Clopidogrel
description: Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
arm group label: Clopidogrel
other name: Plavix
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Yongwhi Park, MD., PhD.
role: Principal Investigator
affiliation: Gyeongsang National University Hospital
last name: Young-Hoon Jeong, MD.,PhD.
role: Principal Investigator
affiliation: Gyeongsan National University Hospital
last name: Yongwhi Park, MD.,PhD.
phone: +82-55-750-8059
email: angio2000@hanmail.net
last name: Young-Hoon Jeong, MD.,PhD.
phone: +82-55-214-3721
email: goodoctor@naver.com
facility: 
status: Not yet recruiting
investigator: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
investigator: 
facility: 
status: Recruiting
investigator: 
facility: 
status: Recruiting
investigator: 
facility: 
status: Recruiting
investigator: 
facility: 
status: Recruiting
investigator: 
investigator: 
facility: 
status: Recruiting
investigator: 
facility: 
status: Recruiting
investigator: 
facility: 
status: Recruiting
investigator: 
facility: 
status: Active, not recruiting
country: China
country: Korea, Republic of
country: Singapore
responsible party type: Principal Investigator
investigator affiliation: Gyeongsang National University Hospital
investigator full name: Yongwhi Park
investigator title: MD.,PhD.
mesh term: Myocardial Infarction
mesh term: ST Elevation Myocardial Infarction
mesh term: Infarction
mesh term: Ventricular Remodeling
mesh term: Clopidogrel
mesh term: Ticagrelor
sharing ipd: No